BOTHELL, Wash., Feb. 17 /PRNewswire-FirstCall/ -- Cardiac Science (Nasdaq: CSCX), a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, today announced today that it will present at the Roth 21st Annual OC Growth Stock Conference at the Ritz Carlton Laguna Nigel. John Hinson, president and chief executive officer, will review the Company's business strategy and recent financial results during the Company's presentation on Wednesday, February 18 at 11:30 a.m. local time.
Attendance at the conference is by invitation only. Cardiac Science will offer a live audio webcast of its presentation, which may be accessed at the Company's website at www.cardiacscience.com. An archived replay of the presentation will also be available following the live presentation and can be accessed at www.cardiacscience.com.
About Cardiac Science
Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.
Forward Looking Statements
This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's expectations regarding revenues for the fourth quarter and full year 2008, charges relating to the restructuring announced in this press release, and expectations regarding the impact of the restructuring on 2009 operating results. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in Cardiac Science Corporation's Annual Report on Form 10-K for the year ended December 31, 2007 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2008. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
For more information, Company Contact: Investor Contact: Media Contact: Mike Matysik Doug Sherk Christopher Gale Cardiac Science Corporation Jenifer Kirtland EVC Group Inc. Senior Vice President and CFO EVC Group Inc. 646.201.5431 425.402.2009 415.896.6820 203.570.4681 email@example.com
|SOURCE Cardiac Science|
Copyright©2009 PR Newswire.
All rights reserved